AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37699709 — intervention group
Group type: EXPERIMENTAL
Intervention: Single subcutaneous KPL-404 dose 1 or 5 mg/kg
Number of subjects: 0
Study 37699709 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 37699719 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 3157
Study 37699719 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediabetes
Number of subjects: 3157
Study 37699719 — intervention group
Group type: COMPARATOR
Intervention: No diabetes
Number of subjects: 3157
Study 37699726 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-CDSS intervention group
Number of subjects: 21689
Study 37699726 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 21689
Study 37699851 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (LZ) 5 mg co-treatment during ovarian stimulation
Number of subjects: 159
Study 37699851 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study 37700015 — intervention group
Group type: EXPERIMENTAL
Intervention: Transanal TME (taTME)
Number of subjects: 100
Study 37700101 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D printed models in addition to standard CT imaging
Number of subjects: 0
Study 37700101 — intervention group
Group type: COMPARATOR
Intervention: Standard CT imaging alone
Number of subjects: 0
Study 37700239 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT) combining aspirin and a P2Y12 inhibitor
Number of subjects: 0
Study 37700239 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 37700241 — intervention group
Group type: EXPERIMENTAL
Intervention: STEPWISE app (intervention arm with increases of 25-100%)
Number of subjects: 452
Study 37700241 — intervention group
Group type: EXPERIMENTAL
Intervention: STEPWISE app (intervention arm with increases of 50-200%)
Number of subjects: 452
Study 37700241 — intervention group
Group type: EXPERIMENTAL
Intervention: STEPWISE app (intervention arm with increases of 100-400%)
Number of subjects: 452
Study 37700241 — intervention group
Group type: COMPARATOR
Intervention: Active control group (increase of 5-20%)
Number of subjects: 452
Study 37700241 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical fitness, motor- and non-motor function measures
Number of subjects: 452
Study 37700241 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-response relationship
Number of subjects: 452
Study 37700245 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Health Intervention (DHI)
Number of subjects: 258
Study 37700249 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous ascorbic acid (50 mg/kg every 6 h for 96 h)
Number of subjects: 23
Study 37700249 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 37700288 — intervention group
Group type: EXPERIMENTAL
Intervention: Eat, Walk, Sleep (EWS)
Number of subjects: 188
Study 37700288 — intervention group
Group type: EXPERIMENTAL
Intervention: EWS plus medication therapy management (EWS + MTM)
Number of subjects: 188
Study 37700288 — intervention group
Group type: COMPARATOR
Intervention: Social services (SS)
Number of subjects: 188
Study 37700288 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 188
Study 37700317 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 infection
Number of subjects: 425
Study 37700334 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily smartphone-based monitoring and treatment including clinical feedback
Number of subjects: 201
Study 37700334 — intervention group
Group type: COMPARATOR
Intervention: Daily smartphone-based monitoring without clinical feedback
Number of subjects: 201
Study 37700334 — intervention group
Group type: COMPARATOR
Intervention: Daily smartphone-based mood monitoring only
Number of subjects: 201
Study 37700348 — intervention group
Group type: COMPARATOR
Intervention: PF regimen (cisplatin and 5-fluorouracil)
Number of subjects: 86
Study 37700348 — intervention group
Group type: EXPERIMENTAL
Intervention: DP regimen (docetaxel and cisplatin)
Number of subjects: 86
Study 37700348 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage treatment
Number of subjects: 86
Study 37700348 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 86
Study 37700375 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 80
Study 37700375 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin intervention
Number of subjects: 80
Study 37700375 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 80
Study 37700443 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide 5 mg
Number of subjects: 0
Study 37700443 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide 10 mg
Number of subjects: 0
Study 37700443 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide 15 mg
Number of subjects: 0
Study 37700443 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37700443 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide (all doses)
Number of subjects: 0
Study 37700689 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime/avibactam (plus metronidazole for cIAI)
Number of subjects: 813
Study 37700689 — intervention group
Group type: COMPARATOR
Intervention: Comparator (carbapenems in >97% of patients)
Number of subjects: 813
Study 37700687 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher fractions of inspired oxygen (FiO2)
Number of subjects: 10385
Study 37700687 — intervention group
Group type: COMPARATOR
Intervention: Lower fractions of inspired oxygen (FiO2)
Number of subjects: 10385
Study 37700695 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical dry needling
Number of subjects: 64
Study 37700695 — intervention group
Group type: COMPARATOR
Intervention: Non-invasive multicomponent intervention
Number of subjects: 64
Study 37700773 — intervention group
Group type: EXPERIMENTAL
Intervention: Transpulmonary pressure-guided PEEP with electrical impedance tomography (EIT)
Number of subjects: 1
Study 37701088 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspiration of endometrial cavity fluid with diosmin intake
Number of subjects: 200
Study 37701088 — intervention group
Group type: COMPARATOR
Intervention: Control group (conservative management)
Number of subjects: 200
Study 37701986 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab-based combination therapy
Number of subjects: 0
Study 37701986 — intervention group
Group type: COMPARATOR
Intervention: Pembrolizumab monotherapy
Number of subjects: 0
Study 37702047 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary nitrate supplementation (400 mg nitrate in 70 mL beetroot juice)
Number of subjects: 55
Study 37702079 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 8242
Study 37702079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8242
Study 37702300 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant vitamins (vitamin C, E, beta-carotene, and zinc)
Number of subjects: 11952
Study 37702300 — intervention group
Group type: COMPARATOR
Intervention: Lutein/zeaxanthin
Number of subjects: 11952
Study 37702300 — intervention group
Group type: COMPARATOR
Intervention: Zinc
Number of subjects: 11952
Study 37702300 — intervention group
Group type: COMPARATOR
Intervention: Vitamin E
Number of subjects: 11952
Study 37702300 — intervention group
Group type: COMPARATOR
Intervention: Multivitamin (including lutein/zeaxanthin)
Number of subjects: 11952
Study 37702300 — intervention group
Group type: COMPARATOR
Intervention: Beta-carotene
Number of subjects: 11952
Study 37702300 — intervention group
Group type: COMPARATOR
Intervention: Visual Function Questionnaire
Number of subjects: 11952
Study 37702406 — intervention group
Group type: EXPERIMENTAL
Intervention: Pola-R-CHP (polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin and prednisone)
Number of subjects: 0
Study 37702406 — intervention group
Group type: COMPARATOR
Intervention: R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone)
Number of subjects: 0
Study 37702427 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antibiotics (OA) combined with mechanical bowel preparation (MBP)
Number of subjects: 309
Study 37702427 — intervention group
Group type: COMPARATOR
Intervention: Mechanical bowel preparation (MBP)
Number of subjects: 309
Study 37702442 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous antibiotic prophylaxis
Number of subjects: 292
Study 37702442 — intervention group
Group type: COMPARATOR
Intervention: No treatment (untreated group)
Number of subjects: 292
Study 37702453 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical pilocarpine HCl 1.25% (Pilo)
Number of subjects: 375
Study 37702453 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 375
Study 37702588 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus 25 mg i.v. on days 1, 8, 15, and 22 and bevacizumab 10 mg/kg i.v. on days 1 and 15 of a 4-week cycle
Number of subjects: 59
Study 37702588 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus and bevacizumab combination therapy
Number of subjects: 59
Study 37702588 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Number of subjects: 59
Study 37702588 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 59
Study 37702912 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-facilitated, manualized, 7-session group intervention
Number of subjects: 143
Study 37702912 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 143
Study 37702920 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotrovimab 500 mg (intravenous infusion on Day 1)
Number of subjects: 1057
Study 37702920 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1057
Study 37702920 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotrovimab 500 mg
Number of subjects: 1057
Study 37703006 — intervention group
Group type: EXPERIMENTAL
Intervention: Evinacumab, 15 mg/kg, intravenously Q4W
Number of subjects: 96
Study 37703015 — intervention group
Group type: EXPERIMENTAL
Intervention: Green labels ("choose often")
Number of subjects: 7945
Study 37703015 — intervention group
Group type: EXPERIMENTAL
Intervention: Traffic light labels
Number of subjects: 7945
Study 37703015 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity calorie equivalent labels
Number of subjects: 7945
Study 37703015 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient warning labels
Number of subjects: 7945
Study 37703015 — intervention group
Group type: COMPARATOR
Intervention: Calorie labels only (control)
Number of subjects: 7945
Study 37703030 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute exercise (60 min at 61% of peak oxygen uptake)
Number of subjects: 20
Study 37703030 — intervention group
Group type: COMPARATOR
Intervention: Control (rest and high-fat meals)
Number of subjects: 20
Study 37703037 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy (DBT) for 1 year (36 sessions)
Number of subjects: 100
Study 37703037 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC) psychotherapy (schedule clinically determined) for 1 year
Number of subjects: 100
Study 37703037 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy (DBT)
Number of subjects: 100
Study 37703083 — intervention group
Group type: EXPERIMENTAL
Intervention: Elexacaftor/Tezacaftor/Ivacaftor treatment
Number of subjects: 0
Study 37703082 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-yoga intervention
Number of subjects: 89
Study 37703248 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (MBI) delivered by ecological momentary intervention (EMI) via a smartphone app, including daily practice prompts, mindfulness exercises, virtual counseling, and daily psychological status logs.
Number of subjects: 670
Study 37703248 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (MBI) delivered by ecological momentary intervention (EMI) via a smartphone app.
Number of subjects: 670
Study 37703248 — intervention group
Group type: COMPARATOR
Intervention: Audio-based standardized mindfulness practice instructions three times per week (control group).
Number of subjects: 670
Study 37703330 — intervention group
Group type: EXPERIMENTAL
Intervention: Cut-point-free metrics (Intensity Gradient - IG)
Number of subjects: 530
Study 37703330 — intervention group
Group type: EXPERIMENTAL
Intervention: Cut-point-free metrics (Average Acceleration - AvAcc)
Number of subjects: 530
Study 37703330 — intervention group
Group type: EXPERIMENTAL
Intervention: Cut-point-based metrics (moderate-to-vigorous and vigorous activity)
Number of subjects: 530
Study 37703330 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference values for IG and AvAcc
Number of subjects: 530
Study 37703353 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1283
Number of subjects: 0
Study 37703353 — intervention group
Group type: COMPARATOR
Intervention: mRNA-1273
Number of subjects: 0
Study 37703397 — intervention group
Group type: EXPERIMENTAL
Intervention: Open lidocaine administration
Number of subjects: 47
Study 37703397 — intervention group
Group type: EXPERIMENTAL
Intervention: Open capsaicin administration
Number of subjects: 47
Study 37703397 — intervention group
Group type: COMPARATOR
Intervention: Hidden lidocaine administration
Number of subjects: 47
Study 37703397 — intervention group
Group type: COMPARATOR
Intervention: Hidden capsaicin administration
Number of subjects: 47
Study 37703482 — intervention group
Group type: EXPERIMENTAL
Intervention: 68 Ga-DOTATATE PET/CT
Number of subjects: 220
Study 37703506 — intervention group
Group type: EXPERIMENTAL
Intervention: Magrolimab with azacitidine
Number of subjects: 87
Study 37703513 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus group discussions with parents regarding meals, traditional foods, beverages, physical activity, and screen time.
Number of subjects: 0
Study 37703908 — intervention group
Group type: COMPARATOR
Intervention: Ciclosporin (2-3 mg/kg before transplantation and 3 mg/kg twice per day from postoperative day 1)
Number of subjects: 249
Study 37703908 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (0.05-0.1 mg/kg before transplantation and 0.1-0.2 mg/kg from postoperative day 1)
Number of subjects: 249
Study 37703908 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 249
Study 37703908 — intervention group
Group type: COMPARATOR
Intervention: Ciclosporin
Number of subjects: 249
Study 37703948 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy (MT) with the FlowTriever System
Number of subjects: 550
Study 37703948 — intervention group
Group type: COMPARATOR
Intervention: Catheter-directed thrombolysis (CDT)
Number of subjects: 550
Study 37703948 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy (MT)
Number of subjects: 550
Study 37703995 — intervention group
Group type: EXPERIMENTAL
Intervention: Omidubicel-onlv
Number of subjects: 108
Study 37704387 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support (CDS) system
Number of subjects: 29771
Study 37704387 — intervention group
Group type: COMPARATOR
Intervention: Dismissed CDS recommendations
Number of subjects: 29771
Study 37704438 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral anterior quadratus lumborum block (30 mL of ropivacaine 0.375%)
Number of subjects: 88
Study 37704438 — intervention group
Group type: COMPARATOR
Intervention: Sham block (normal saline)
Number of subjects: 88
Study 37704499 — intervention group
Group type: EXPERIMENTAL
Intervention: Second booster doses of monovalent COVID-19 vaccines (AZD1222, Ad26.COV2.S, CoronaVac, BNT162b2)
Number of subjects: 30272
Study 37704499 — intervention group
Group type: EXPERIMENTAL
Intervention: First booster doses of monovalent COVID-19 vaccines
Number of subjects: 30272
Study 37704499 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD1222 as second booster
Number of subjects: 30272
Study 37704499 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 as second booster
Number of subjects: 30272
Study 37704499 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD1222 as first booster
Number of subjects: 30272
Study 37704499 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 as first booster
Number of subjects: 30272
Study 37704533 — intervention group
Group type: EXPERIMENTAL
Intervention: CESAR© intervention (training course for community pharmacists and smoking cessation service)
Number of subjects: 800
Study 37704533 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 800
Study 37704533 — intervention group
Group type: EXPERIMENTAL
Intervention: CESAR© intervention
Number of subjects: 800
Study 37704534 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapeutic Follow-up Program (6 months)
Number of subjects: 123
Study 37704579 — intervention group
Group type: EXPERIMENTAL
Intervention: Luspatercept therapy
Number of subjects: 0
Study 37704753 — intervention group
Group type: EXPERIMENTAL
Intervention: CDK4/6 inhibitors (palbociclib) in combination with aromatase inhibitors (AI) or fulvestrant (FUL)
Number of subjects: 280
Study 37704799 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta variant wave
Number of subjects: 160
Study 37704799 — intervention group
Group type: EXPERIMENTAL
Intervention: Omicron variant wave
Number of subjects: 160
Study 37704799 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-Delta variant wave
Number of subjects: 160
Study 37704799 — intervention group
Group type: EXPERIMENTAL
Intervention: Omicron cluster positives
Number of subjects: 160
Study 37704916 — intervention group
Group type: EXPERIMENTAL
Intervention: Peroxide-containing whitening toothpastes
Number of subjects: 199
Study 37704916 — intervention group
Group type: COMPARATOR
Intervention: Control/conventional toothpaste
Number of subjects: 199
Study 37704942 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation (two oral capsules daily for three months)
Number of subjects: 0
Study 37704977 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterocervical angle
Number of subjects: 70
Study 37704977 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical length
Number of subjects: 70
Study 37704984 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga for chronic pain (10 weeks)
Number of subjects: 75
Study 37704984 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-Behavioral Therapy (CBT) for chronic pain (10 weeks)
Number of subjects: 75
Study 37705043 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote monitoring with digital sensors measuring fat mass using Withing's bioimpedance scale over a median of 10 weeks
Number of subjects: 15
Study 37705043 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Frailty Score (CFS) assessment
Number of subjects: 15
Study 37705074 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile-based coaching intervention (WeChat mini-program) with 180 educational videos for 6 months and standard treatment
Number of subjects: 820
Study 37705074 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 820
Study 37705093 — intervention group
Group type: EXPERIMENTAL
Intervention: Science of Service Laboratory (SSL) implementation strategy
Number of subjects: 10
Study 37705105 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-related impacts on interpersonal conflict
Number of subjects: 188
Study 37705105 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-related impacts on employment
Number of subjects: 188
Study 37705105 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-related impacts on infection exposure
Number of subjects: 188
Study 37705327 — intervention group
Group type: EXPERIMENTAL
Intervention: Mezigdomide (0.4-3.2 mg single oral doses)
Number of subjects: 64
Study 37705327 — intervention group
Group type: COMPARATOR
Intervention: High-fat meal
Number of subjects: 64
Study 37705327 — intervention group
Group type: COMPARATOR
Intervention: Proton pump inhibitor (PPI)
Number of subjects: 64
Study 37705369 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid approach using drug-eluting stent (DES) and drug-coated balloon (DCB)
Number of subjects: 106
Study 37705424 — intervention group
Group type: EXPERIMENTAL
Intervention: Alglucosidase alfa 20 mg/kg body weight, single intravenous dose
Number of subjects: 20
Study 37705424 — intervention group
Group type: EXPERIMENTAL
Intervention: Alglucosidase alfa in anti-alglucosidase alfa-negative participants (n = 12)
Number of subjects: 20
Study 37705424 — intervention group
Group type: EXPERIMENTAL
Intervention: Alglucosidase alfa in anti-alglucosidase alfa-positive participants (n = 7)
Number of subjects: 20
Study 37705497 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanubrutinib as second-line treatment
Number of subjects: 112
Study 37705972 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab combined with daratumumab
Number of subjects: 0
Study 37705972 — intervention group
Group type: COMPARATOR
Intervention: Monoclonal antibodies (including rituximab and abatacept)
Number of subjects: 0
Study 37705972 — intervention group
Group type: COMPARATOR
Intervention: Steroids
Number of subjects: 0
Study 37706025 — intervention group
Group type: EXPERIMENTAL
Intervention: Wharton Jelly-derived Mesenchymal Stromal Cells (WJ-MSCs) - 1 intravenous infusion of 1 × 10
Number of subjects: 30
Study 37706025 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 37706171 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutaneous vibrotactile stimulation of the hand
Number of subjects: 14
Study 37706171 — intervention group
Group type: COMPARATOR
Intervention: Muscle stimulation
Number of subjects: 14
Study 37706171 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 14
Study 37706457 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular Point Acupressure (APA) treatment administered by nurses for 3 days, with patients instructed to stimulate the points 3 times per day for 3 minutes each time.
Number of subjects: 33
Study 37706527 — intervention group
Group type: EXPERIMENTAL
Intervention: Anifrolumab 300 mg
Number of subjects: 21
Study 37706527 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 37706580 — intervention group
Group type: EXPERIMENTAL
Intervention: ATG-targeted dosing strategy
Number of subjects: 66
Study 37706580 — intervention group
Group type: COMPARATOR
Intervention: Conventional fixed ATG dose (historical control)
Number of subjects: 66